TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37518975

Group type: EXPERIMENTAL
Intervention: Fecal elastase-1 (FE-1) levels >500 µg/g
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Weight gain posttransplant
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Correlation analysis between weight gain and FE-1, pretransplant C-peptide levels, or duration of diabetes
Number of subjects: 42
Study: 37519033

Group type: EXPERIMENTAL
Intervention: Hypertonic glucose (HG) 75%
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Sodium tetradecyl sulfate (STS) 0.05%
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Sodium tetradecyl sulfate (STS) 0.1%
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Sodium tetradecyl sulfate (STS) 0.15%
Number of subjects: 116
Study: 37519897

Group type: EXPERIMENTAL
Intervention: Supportive digital tools (digital diaries and/or wearables)
Number of subjects: 157

Group type: COMPARATOR
Intervention: No supportive digital tools
Number of subjects: 157
Study: 37519971

Group type: EXPERIMENTAL
Intervention: Regenerative endodontic therapy (RET) with modified triple antibiotic paste (mTAP)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Regenerative endodontic therapy (RET) with Metapex™
Number of subjects: 39

Group type: COMPARATOR
Intervention: Zinc oxide eugenol (ZOE) pulpectomy
Number of subjects: 39
Study: 37520177

Group type: EXPERIMENTAL
Intervention: Fresh mango
Number of subjects: 34

Group type: COMPARATOR
Intervention: Dried mango
Number of subjects: 34
Study: 37520237

Group type: EXPERIMENTAL
Intervention: MDMA-assisted therapy (MDMA-AT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Delayed treatment (control)
Number of subjects: 20
Study: 37520311

Group type: EXPERIMENTAL
Intervention: Standardised field-based 8 min exercise challenge test (ECT) at 85% maximal heart rate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Unstandardised field-based exercise challenge test (ECT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Eucapnic voluntary hyperpnoea (EVH) and methacholine bronchial provocation test (BPT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standardised field-based ECT
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unstandardised field-based ECT
Number of subjects: 60

Group type: COMPARATOR
Intervention: EVH and methacholine BPT
Number of subjects: 60
Study: 37520411

Group type: EXPERIMENTAL
Intervention: 2000 mg IV sotrovimab
Number of subjects: 81
Study: 37520420

Group type: EXPERIMENTAL
Intervention: DTG/3TC
Number of subjects: 741

Group type: COMPARATOR
Intervention: TAF-based regimen
Number of subjects: 741
Study: 37520827

Group type: EXPERIMENTAL
Intervention: Low-amount/moderate-intensity exercise (10 kcal/kg/week at 50% peak)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-amount/moderate-intensity exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-amount/vigorous-intensity exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-amount/vigorous-intensity exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined exercise and lifestyle intervention
Number of subjects: 0
Study: 37521160

Group type: EXPERIMENTAL
Intervention: Quit and Stay Quit Monday intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (standard smoking cessation services)
Number of subjects: 50
Study: 37521410

Group type: EXPERIMENTAL
Intervention: Hydrogen-rich coral calcium (HRCC) capsules (low, medium, and high doses)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hydrogen-rich coral calcium (HRCC) capsules
Number of subjects: 16
Study: 37521498

Group type: EXPERIMENTAL
Intervention: Limiting recreational digital screen use to less than 3 hours/week/person
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 164
Study: 37522086

Group type: EXPERIMENTAL
Intervention: Vienna TAVI system
Number of subjects: 10
Study: 37522226

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg plus ezetimibe 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatments combined
Number of subjects: 0
Study: 37522330

Group type: EXPERIMENTAL
Intervention: NeoLight Skylife phototherapy device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing phototherapy treatment
Number of subjects: 0
Study: 37522361

Group type: EXPERIMENTAL
Intervention: Twin Block
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (fixed appliance)
Number of subjects: 40
Study: 37522415

Group type: EXPERIMENTAL
Intervention: Oxytocin 240 IU inhaled
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxytocin 5 IU intravenous
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxytocin 10 IU intramuscular
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood collected into EDTA tubes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood collected into lithium heparin (LH) tubes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood collected into EDTA-containing collection tubes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood from late-stage pregnancy compared to nonpregnant participants
Number of subjects: 0
Study: 37522479

Group type: EXPERIMENTAL
Intervention: rIX-FP (IDELVION) at 50 IU/kg once a week
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Modified rIX-FP regimen at 40 IU/kg twice/week
Number of subjects: 1
Study: 37522931

Group type: EXPERIMENTAL
Intervention: Tomo-AC
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Tomo-NoAC
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Planar
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: SPECT/CT
Number of subjects: 23
Study: 37523143

Group type: EXPERIMENTAL
Intervention: Vutrisiran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (external placebo group from the APOLLO study)
Number of subjects: 0
Study: 37523163

Group type: EXPERIMENTAL
Intervention: Preemie Prep for Parents (P3) program
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (patient education webpages from the American College of Obstetricians and Gynecologists)
Number of subjects: 120
Study: 37523175

Group type: EXPERIMENTAL
Intervention: Insulin-Only iLet Bionic Pancreas
Number of subjects: 0
Study: 37523194

Group type: EXPERIMENTAL
Intervention: Home hemodialysis (HD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-center HD
Number of subjects: 0
Study: 37523315

Group type: EXPERIMENTAL
Intervention: Pharmacist educational program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer educational program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 37523426

Group type: EXPERIMENTAL
Intervention: Cataract surgery within 4 weeks
Number of subjects: 292

Group type: COMPARATOR
Intervention: Control group (surgery 1 year later)
Number of subjects: 292
Study: 37523429

Group type: EXPERIMENTAL
Intervention: Repeated low-level red-light (RLRL) therapy
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 143
Study: 37523477

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pills (OCPs)
Number of subjects: 3723

Group type: EXPERIMENTAL
Intervention: Continuous use of OCPs
Number of subjects: 3723

Group type: COMPARATOR
Intervention: OCPs
Number of subjects: 3723

Group type: COMPARATOR
Intervention: Standard regimen of OCPs
Number of subjects: 3723
Study: 37523623

Group type: EXPERIMENTAL
Intervention: Multimodal deep learning (DL) classifier using wide OCT optic nerve head cube scans
Number of subjects: 633

Group type: COMPARATOR
Intervention: Texture-based en face image
Number of subjects: 633

Group type: COMPARATOR
Intervention: RNFL thickness map
Number of subjects: 633

Group type: COMPARATOR
Intervention: cSLO image
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Multimodal DL model in highly myopic eyes
Number of subjects: 633

Group type: COMPARATOR
Intervention: Texture en face image in highly myopic eyes
Number of subjects: 633

Group type: COMPARATOR
Intervention: RNFL in highly myopic eyes
Number of subjects: 633

Group type: COMPARATOR
Intervention: cSLO image models in highly myopic eyes
Number of subjects: 633
Study: 37523624

Group type: EXPERIMENTAL
Intervention: Preoperative Chemoradiation with Pazopanib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative Chemoradiation without Pazopanib
Number of subjects: 0
Study: 37523661

Group type: EXPERIMENTAL
Intervention: Lenvatinib (20 mg orally once daily) plus Pembrolizumab (200 mg intravenously every 3 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy (doxorubicin or paclitaxel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lenvatinib plus Pembrolizumab
Number of subjects: 0
Study: 37523939

Group type: EXPERIMENTAL
Intervention: Multidisciplinary pharmacological optimization in the context of a Comprehensive Geriatric Assessment (CGA) with usual care follow-up (∼3 and ∼6 months)
Number of subjects: 104
Study: 37524096

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg oral daily for 54 weeks
Number of subjects: 1545

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1545

Group type: EXPERIMENTAL
Intervention: Everolimus in very-high-risk group
Number of subjects: 1545

Group type: EXPERIMENTAL
Intervention: Everolimus in intermediate-high-risk group
Number of subjects: 1545

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 1545
Study: 37524101

Group type: EXPERIMENTAL
Intervention: Ferric derisomaltose plus tranexamic acid
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Iron plus placebo
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Tranexamic acid plus placebo
Number of subjects: 413

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 413
Study: 37524110

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 76

Group type: COMPARATOR
Intervention: Exenatide
Number of subjects: 76
Study: 37524198

Group type: EXPERIMENTAL
Intervention: Celiac disease (CeD) patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 30
Study: 37524201

Group type: EXPERIMENTAL
Intervention: AZD7442 (tixagevimab/cilgavimab) 300 or 600 mg intramuscularly or 300 or 1000 mg intravenously
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: AZD7442 (tixagevimab/cilgavimab)
Number of subjects: 40
Study: 37524230

Group type: EXPERIMENTAL
Intervention: RG6346 at 1.5 mg/kg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: RG6346 at 3.0 mg/kg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: RG6346 at 6.0 mg/kg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 37524522

Group type: EXPERIMENTAL
Intervention: PAH group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal PAP group
Number of subjects: 100
Study: 37524523

Group type: EXPERIMENTAL
Intervention: SIMEOX device with telecare training
Number of subjects: 22
Study: 37524953

Group type: EXPERIMENTAL
Intervention: Zolbetuximab plus CAPOX
Number of subjects: 507

Group type: COMPARATOR
Intervention: Placebo plus CAPOX
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Zolbetuximab
Number of subjects: 507

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study: 37525000

Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Number of subjects: 674

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 674
Study: 37525110

Group type: EXPERIMENTAL
Intervention: Prenatal mindfulness program (8-week course)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Usual standard prenatal care (Control)
Number of subjects: 102
Study: 37525125

Group type: EXPERIMENTAL
Intervention: Virtual group-based acceptance and commitment therapy (n=35)
Number of subjects: 70
Study: 37525161

Group type: EXPERIMENTAL
Intervention: Body Confident Athletes (BCA) intervention
Number of subjects: 1036

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 1036
Study: 37525207

Group type: EXPERIMENTAL
Intervention: Culturally adapted manual-assisted problem-solving intervention (CMAP) plus enhanced treatment as usual (E-TAU)
Number of subjects: 901

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (E-TAU)
Number of subjects: 901
Study: 37525253

Group type: EXPERIMENTAL
Intervention: Mobile and technology-assisted aftercare intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard services available for individuals discharging from a CSU
Number of subjects: 24
Study: 37525257

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 37525258

Group type: EXPERIMENTAL
Intervention: SV prevention intervention at intervention campuses
Number of subjects: 28
Study: 37525267

Group type: EXPERIMENTAL
Intervention: Practice facilitation intervention by certified practice facilitators (PFs) over 12 months
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Practice facilitation intervention by certified practice facilitators (PFs)
Number of subjects: 32
Study: 37525278

Group type: EXPERIMENTAL
Intervention: Autologous leukocyte- and platelet-rich fibrin (L-PRF) membranes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercially available fibrin sealants
Number of subjects: 0
Study: 37525298

Group type: EXPERIMENTAL
Intervention: Treated participants (n=471, 62%) who self-reported accessing BN/BED treatment at some point in their lives
Number of subjects: 762

Group type: COMPARATOR
Intervention: Untreated participants (n=291, 38%) who never accessed treatment
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Individuals with a history of inpatient or residential treatment
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Individuals with outpatient treatment
Number of subjects: 762
Study: 37525354

Group type: EXPERIMENTAL
Intervention: Intensive SBP control (target of 110 to <130 mmHg)
Number of subjects: 8283
Study: 37525369

Group type: EXPERIMENTAL
Intervention: rabbit antithymocyte globulin (2 × 1.5 mg/kg, postoperative days 0 and 1) and infliximab (5 mg/kg, postoperative day 2) followed by mycophenolate-free tacrolimus-based immunosuppression for 12 mo
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: mycophenolate-free tacrolimus-based immunosuppression
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: study cohort
Number of subjects: 67
Study: 37525373

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Mycophenolate sodium (MPS)
Number of subjects: 266
Study: 37525414

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted transversus abdominis plane block (L-TAPB)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Ultrasound-guided transversus abdominis plane block (U-TAPB)
Number of subjects: 112
Study: 37525559

Group type: EXPERIMENTAL
Intervention: Supervised concurrent exercise training program
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study: 37525592

Group type: EXPERIMENTAL
Intervention: IV edaravone (edaravone-first group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (placebo-first group)
Number of subjects: 0
Study: 37525914

Group type: EXPERIMENTAL
Intervention: GJA4 variants (homozygous G variant, n = 84; 73%)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: TGFβ1 variants
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: GJA4 variants
Number of subjects: 115
Study: 37525973

Group type: EXPERIMENTAL
Intervention: Classical trigeminal neuralgia
Number of subjects: 55

Group type: COMPARATOR
Intervention: Idiopathic trigeminal neuralgia
Number of subjects: 55
Study: 37525974

Group type: EXPERIMENTAL
Intervention: Outdoor cold air (<10°C) exposure for 30 minutes
Number of subjects: 118

Group type: COMPARATOR
Intervention: Indoor room temperature exposure for 30 minutes
Number of subjects: 118
Study: 37526012

Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37526060

Group type: EXPERIMENTAL
Intervention: 25 mg daridorexant
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 4
Study: 37526103

Group type: EXPERIMENTAL
Intervention: Total Gastrectomy (TG)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Distal Gastrectomy (DG)
Number of subjects: 186
Study: 37526117

Group type: EXPERIMENTAL
Intervention: Single-incision robotic assisted surgery (SIRAS)
Number of subjects: 7
Study: 37526149

Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan (Dato-DXd) 6 mg/kg iv. every 3 weeks
Number of subjects: 600

Group type: COMPARATOR
Intervention: Investigator's choice of chemotherapy (ICC)
Number of subjects: 600
Study: 37526194

Group type: EXPERIMENTAL
Intervention: Intensive glycaemic control
Number of subjects: 2670

Group type: COMPARATOR
Intervention: Conventional glycaemic control
Number of subjects: 2670
Study: 37526237

Group type: EXPERIMENTAL
Intervention: Acute exercise (various conditions)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Rest condition
Number of subjects: 51
Study: 37526261

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 3361

Group type: COMPARATOR
Intervention: Percutaneous nephrolithotomy (PCNL)
Number of subjects: 3361

Group type: COMPARATOR
Intervention: Retrograde intrarenal surgery (RIRS)
Number of subjects: 3361
Study: 37526355

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37526436

Group type: EXPERIMENTAL
Intervention: Multiple benzodiazepine receptor agonists
Number of subjects: 0
Study: 37526548

Group type: EXPERIMENTAL
Intervention: Deep learning algorithm using current and prior low-dose CT examination
Number of subjects: 4902

Group type: COMPARATOR
Intervention: Validated DL algorithm that only processed a single CT examination
Number of subjects: 4902
Study: 37526694

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 49
Study: 37526718

Group type: EXPERIMENTAL
Intervention: Upfront radiosurgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wait-and-scan approach
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 100
Study: 37526748

Group type: EXPERIMENTAL
Intervention: Extended complete mesocolic excision (e-CME)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard complete mesocolic excision (s-CME)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: High tie of the inferior mesenteric artery during sigmoidectomy
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Treatment arm
Number of subjects: 79
Study: 37526752

Group type: EXPERIMENTAL
Intervention: Preoperative PECS block (PreM)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Postoperative PECS block (PostM)
Number of subjects: 34
Study: 37526856

Group type: EXPERIMENTAL
Intervention: Medium-dose MF/IND/GLY
Number of subjects: 1930

Group type: COMPARATOR
Intervention: High-dose ICS/LABA
Number of subjects: 1930
Study: 37526883

Group type: EXPERIMENTAL
Intervention: Articaine 4%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lidocaine 2%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Articaine 4% and Lidocaine 2%
Number of subjects: 20
Study: 37526908

Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo or active comparators (semaglutide 1 mg, insulin degludec, insulin glargine)
Number of subjects: 0
Study: 37526934

Group type: EXPERIMENTAL
Intervention: Dural-puncture epidural (DPE)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard epidural
Number of subjects: 140
Study: 37526936

Group type: EXPERIMENTAL
Intervention: Orteronel 300 mg orally twice daily
Number of subjects: 1313

Group type: COMPARATOR
Intervention: Bicalutamide 50 mg orally daily
Number of subjects: 1313
Study: 37526937

Group type: EXPERIMENTAL
Intervention: 6-month aerobic exercise intervention
Number of subjects: 134

Group type: COMPARATOR
Intervention: Attention control (weekly health education telephone calls)
Number of subjects: 134
Study: 37526959

Group type: EXPERIMENTAL
Intervention: Web-Based Management of Adolescent Pain (WebMAP)
Number of subjects: 34
Study: 37527039

Group type: EXPERIMENTAL
Intervention: Omicron BA.4/BA.5 breakthrough infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T cell responses of mRNA-vaccinated individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: B cell immunity
Number of subjects: 0
Study: 37527424

Group type: EXPERIMENTAL
Intervention: Core warming intervention
Number of subjects: 19
Study: 37527479

Group type: EXPERIMENTAL
Intervention: Baseline employment
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Psychotic disorder other than schizophrenia
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Longer duration of untreated psychosis
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Substance use
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Symptom remission without antipsychotic medication
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Recovery
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Substance use during follow-up
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: All chronic illnesses
Number of subjects: 578
Study: 37527726

Group type: EXPERIMENTAL
Intervention: Autologous cord blood mononucleated cells (CBMNCs) delivered via intracoronary infusion during Norwood procedure, 4 doses of 15 mL each, without prior cryopreservation.
Number of subjects: 13
Study: 37527730

Group type: COMPARATOR
Intervention: Best Practices (BP)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Best Practices plus Financial Incentives (BP + FI)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Best Practices plus Financial Incentives and Nicotine Replacement Therapy (BP + FI + NRT)
Number of subjects: 198
Study: 37527856

Group type: EXPERIMENTAL
Intervention: Standard physical therapy (PT)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Internet-based exercise training (IBET)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Usual care/wait list control
Number of subjects: 303